Saving Lives With AI-Powered Immunotherapies

Featured news

Evaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01

Evaxion is set to present promising clinical data from its EVX-01 Phase 1 clinical trial in metastatic melanoma on June 3, at the 2023 ASCO annual meeting, in Chicago, Illinois.

Evaxion focuses on ERVs for personalized cancer immunotherapy

Evaxion has developed a new proprietary AI platform technology ObsERV™ to identify a new source of targets for personalized cancer therapy, potentially enabling treatment of patients that are currently considered unresponsive to cancer immunotherapy.

Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients

Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapy. This potentially enables treatment for patients with cold tumors, normally unresponsive to immunotherapy

Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)

Evaxion announced that the company will present clinical readout of the Phase 1/2a trial of EVX-02 at the upcoming 2023 American Association for Cancer Research Annual Meeting (2023 AACR), taking place from April 14th to April 19th in Orlando, Florida.

Birgitte Rønø Chief Scientific Officer Evaxion

Evaxion and Pantherna announce promising preclinical mRNA vaccine data

Evaxion and Pantherna announced that the tumor neoantigens, identified by Evaxion's PIONEER, demonstrates strong immune response.

Interview about the ObsERV platform with CEO, Per Norlén

CEO Per Norlén interviewed about our new ObsERV platform

Company presentation

Are you eager to deep-dive into Evaxion's business? Download our latest presentation below, or click here to see all our latest presentations.

Download

Learn more about Evaxion

AI Technology

We're advancing a robust product pipeline through our state-of-the-art platforms in cancer and infectious disease. Our focus is on drug discovery and early drug development, with an eye towards a future that reimagines the way cancer and infectious diseases are treated - and even cured.

News

Click here and find the latest news, presentations, and publications from Evaxion.

Careers

We are 70 hearts and minds working closely together in a fully integrated AI and research facility in Hørsholm just north of Copenhagen. As pioneers and leaders in AI-powered immunotherapy, we seek, employ and develop the best scientific minds and extraordinarily skilled people.

Investor Relations

Our Investor Relations portal contains information about Evaxion's business for stockholders, potential investors, and financial analysts.

With our artificial intelligence technology, we harness the power of the human immune system to create novel immunotherapies for the patients of today - and tomorrow.

About Us

Subscribe to our Newsletter

Be the first to know about news, milestones and events at Evaxion by subscribing to our newsletter. You'll only hear from us when it's important, and can unsubscribe at any time.